Navigation Links
OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
Date:8/30/2007

Private offering provides new funding as OncoVista, Inc. takes steps

towards public reporting status.

SAN ANTONIO, Aug. 30 /PRNewswire/ -- OncoVista, Inc., a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies with improved efficacy and reduced toxicity, announced the successful completion of a private placement offering and its acquisition of a control position in a public reporting shell company.

OncoVista completed the private sale of 970,712 units of common stock and warrants to new and existing investors raising approximately $6.8 million in gross proceeds. Participants in the offering included Wexford Capital LLC, CAMOFI Master LDC, Bristol Investment Fund, Ltd., as well as other select institutional and qualified investors. Maxim Group, LLC acted as the company's exclusive placement agent in the offering. Contemporaneously with the closing, OncoVista acquired a control position in Aviation Upgrade Technologies, Inc., a Nevada corporation (OTC Bulletin Board: AVUG) and transferred the former operating subsidiary to its former chief executive officer.

"The closing of our financing and our acquisition of a public reporting company in preparation for our becoming a publicly-traded company marks a very exciting and important milestone in OncoVista's history," said Alexander L. Weis, Ph.D., Chairman of the Board of Directors, President and Chief Executive Officer of OncoVista, Inc. "Targeted oncology therapy is an attractive and growing business segment, and our ability to access the public capital market is a tremendous opportunity for further growth of OncoVista," Dr. Weis said.

About OncoVista, Inc.

A biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies both through the acquisition of rights to technologies and drugs from others and through the development of proprietary products. OncoVista intends to identify, develop and rapidly commercialize innovative therapies for safe and efficacious treatment of cancer. By commercializing novel therapeutics, OncoVista plans to capture a significant share of the U.S. market for cancer therapeutics, currently estimated at $32 billion per year and projected to grow to $70 billion by 2010. In addition, OncoVista's proprietary diagnostic technology is expected to facilitate selection of clinical trial participants, as well as to quantify and predict the response of patients to treatment. OncoVista believes that the development of targeted approaches to the administration of anticancer agents will lead to improved outcomes and/or reduced toxicity.


'/>"/>
SOURCE OncoVista, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NimbleGen closes $8.2m venture round, bringing total to $50m
2. BoneCare doubles options and profits as fiscal year closes
3. DEMO 2003 Closes with Focus on Collaboration and Communication
4. Venture Investors early-stage fund grows to $115 million
5. Two convicted of selling $6 million in counterfeit Rockwell software on eBay
6. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
7. TomoTherapy raises $223 million in IPO
8. Fiserv reports $113.5 million in Q1 profit
9. Investors raise $25 million for biodiesel plant
10. Grow Milwaukee includes millions for tech funding
11. Mirus Bio, Pfizer enter multimillion-dollar research agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):